Maryland State Retirement & Pension System Sells 832 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Maryland State Retirement & Pension System lessened its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 7.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 11,089 shares of the company’s stock after selling 832 shares during the period. Maryland State Retirement & Pension System’s holdings in Harmony Biosciences were worth $335,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. TFO Wealth Partners LLC lifted its position in shares of Harmony Biosciences by 98,700.0% during the 4th quarter. TFO Wealth Partners LLC now owns 988 shares of the company’s stock valued at $32,000 after buying an additional 987 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Harmony Biosciences by 47.5% during the fourth quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock valued at $33,000 after purchasing an additional 329 shares in the last quarter. Lazard Asset Management LLC boosted its position in shares of Harmony Biosciences by 98.3% in the first quarter. Lazard Asset Management LLC now owns 4,542 shares of the company’s stock worth $152,000 after purchasing an additional 2,251 shares during the period. SG Americas Securities LLC bought a new position in shares of Harmony Biosciences in the second quarter worth approximately $138,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Harmony Biosciences in the fourth quarter worth $238,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of Harmony Biosciences stock opened at $36.04 on Thursday. The firm has a market cap of $2.05 billion, a PE ratio of 15.60, a PEG ratio of 0.72 and a beta of 0.72. The stock has a 50 day moving average of $33.71 and a 200 day moving average of $31.77. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. The firm had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. Harmony Biosciences’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm posted $0.56 earnings per share. On average, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current fiscal year.

Analyst Ratings Changes

HRMY has been the subject of several recent analyst reports. Citigroup started coverage on shares of Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.67.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.